ClinicalTrials.gg

Program

Enoxaparin

Also written as “Enoxaparin sodium”, “Enoxaparine” and “enoxaparin”.

Its studies are mostly in Venous Thromboembolism · Venous Thrombosis · Myocardial Infarction · Thromboembolism · Acute Coronary Syndrome, led by 11 companies.

Furthest: phase 4, since Feb 12, 200428 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi130 open or runningphase 4since Feb 12, 2004Aug 13, 2002none ahead
Les Laboratoires des Médicaments Stériles40 open or runningphase 4since May 14, 2011May 14, 2011none ahead
Boehringer Ingelheim20 open or runningphase 3since Jul 2, 2014Jul 2, 2014none ahead
Chemi20 open or runningphase 1since Mar 6, 2014Mar 6, 2014none ahead
Bristol-Myers Squibb10 open or runningphase 3since Jan 17, 2007Jan 17, 2007none ahead
Egyptian International Pharmaceutical Industries11 open or runningphase 1since Mar 17, 2026Mar 17, 2026none ahead
Eurofarma Laboratorios10 open or runningphase 3since May 18, 2011May 18, 2011none ahead
Fertility Center of Las Vegas11 open or runningphase 4since Nov 10, 2023Nov 10, 2023none ahead
PT Bio Farma10 open or runningphase 4since Oct 29, 2023Oct 29, 2023none ahead
rovi-pharmaceuticals-laboratories10 open or runningphase 1since Nov 29, 2017Nov 29, 2017none ahead
Venus Remedies10 open or runningphase 1since Feb 22, 2022Feb 22, 2022none ahead

Also a collaborator on its studies: parexel and pra-health-sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 13 studies since Aug 13, 2002.

  1. Jul 24, 2008Phase 3 study in Abdominal NeoplasmsSanofi · NCT00723216 · 151 enrolled · Japan
  2. May 14, 2011Les Laboratoires des Médicaments Stériles's first study: phase 4 study in Venous ThrombosisNew to Les Laboratoires des Médicaments StérilesLes Laboratoires des Médicaments Stériles · NCT01354704 · 153 enrolled · Tunisia
  3. May 18, 2011Eurofarma Laboratorios's first study: phase 3 study in Angina, UnstableNew to Eurofarma LaboratoriosEurofarma Laboratorios · NCT01356992 · 62 enrolled · Brazil
  4. Sep 11, 2012Phase 4 study in Acute Coronary SyndromeLes Laboratoires des Médicaments Stériles · NCT01687491 · 179 enrolled · Tunisia
  5. Mar 6, 2014Chemi's first study: phase 1 study in Clexane is Administered to Healthy VolunteersNew to ChemiChemi · NCT02081950 · 14 enrolled · United Kingdom
  6. Jul 2, 2014Boehringer Ingelheim's first studies: 2 phase 3 studies in Myocardial InfarctionNew to Boehringer IngelheimBoehringer Ingelheim · NCT02181998, NCT02181985
  7. Sep 3, 2014Phase 1 study in Enoxaparin Sodium is Administered to Healthy VolunteersChemi · NCT02232802 · 47 enrolled · United Kingdom
  8. May 7, 2015Phase 4 study in Gastrointestinal NeoplasmsLes Laboratoires des Médicaments Stériles · NCT02444572 · 168 enrolled · Tunisia
  9. Nov 29, 2017rovi-pharmaceuticals-laboratories's first study: phase 1 study in HealthyNew to rovi-pharmaceuticals-laboratoriesrovi-pharmaceuticals-laboratories · NCT03363477 · 46 enrolled
  10. May 7, 2018Phase 4 study in Placental InsufficiencyLes Laboratoires des Médicaments Stériles · NCT03528967 · 89 enrolled · Tunisia
  11. Feb 22, 2022Venus Remedies's first study: phase 1 study in HealthyNew to Venus RemediesVenus Remedies · NCT05265676 · 24 enrolled · India
  12. Oct 29, 2023PT Bio Farma's first study: phase 4 study in Safety IssuesNew to PT Bio FarmaPT Bio Farma · NCT06114641 · 220 enrolled · Indonesia
  13. Nov 10, 2023Fertility Center of Las Vegas's first study: phase 4 study in Infertility, FemaleNew to Fertility Center of Las VegasFertility Center of Las Vegas · NCT06133803 · 130 planned · United States
  14. Mar 17, 2026Egyptian International Pharmaceutical Industries's first study: phase 1 study in Healthy Participants StudyNew to Egyptian International Pharmaceutical IndustriesEgyptian International Pharmaceutical Industries · NCT07517289 · 26 planned

TargetBeta

SERPINC1 →read by rule
“Antithrombin-III activator”ChEMBL 37, by rule

Studies

All 28 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07517289Healthy Participants Study1Not yet recruitingEgyptian International Pharmaceutical IndustriesJun 202626
NCT06133803Infertility, Female · United States4RecruitingFertility Center of Las VegasDec 15, 2024130
NCT06114641Safety Issues · Indonesia4CompletedPT Bio FarmaFeb 5, 2024220
NCT05265676Healthy · India1CompletedVenus RemediesMar 7, 202124
NCT03528967Placental Insufficiency · Tunisia4CompletedLes Laboratoires des Médicaments StérilesJul 31, 201889
NCT03363477Healthy1Completedrovi-pharmaceuticals-laboratoriesDec 1, 201546
NCT02444572Gastrointestinal Neoplasms · Tunisia4CompletedLes Laboratoires des Médicaments StérilesJul 2020168
NCT02232802Enoxaparin Sodium is Administered to Healthy Volunteers · United Kingdom1CompletedChemiDec 5, 201447
NCT02181998Myocardial Infarction3CompletedBoehringer IngelheimAug 20021,606
NCT02181985Myocardial Infarction3CompletedBoehringer IngelheimApr 20015,989
NCT02081950Clexane is Administered to Healthy Volunteers · United Kingdom1CompletedChemiMar 201414
NCT01687491Acute Coronary Syndrome · Tunisia4CompletedLes Laboratoires des Médicaments StérilesMay 2013179
NCT01356992Angina, Unstable · Brazil3TerminatedEurofarma LaboratoriosJul 201362
NCT01354704Venous Thrombosis · Tunisia4CompletedLes Laboratoires des Médicaments StérilesJul 2015153
NCT00723216Abdominal Neoplasms · Japan3CompletedSanofiDec 2007151
NCT00685958Hip Fractures · Japan3CompletedSanofiMar 200754
NCT00622648Acute Illness · Brazil, China, Hong Kong and more4CompletedSanofiDec 20108,329
NCT00622115Thrombosis · France1CompletedSanofiNov 200772
NCT00423319Venous Thrombosis · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbSep 20095,407
NCT00349180Arthroplasty, Replacement, Hip · Japan3CompletedSanofi156
NCT00347490Hemodialysis · Thailand4CompletedSanofiApr 2007100
NCT00265993Venous Thrombosis · Turkey (Türkiye)4CompletedSanofiJan 2009251
NCT00077844Percutaneous Coronary Intervention3CompletedSanofiSep 20053,532
NCT00077818Acute Coronary Syndrome4CompletedSanofiFeb 2005
NCT00077805Ischemic Stroke · United States, Australia, Austria and more4CompletedSanofiJul 2006
NCT00077792Myocardial Infarction · United States, Argentina, Australia and more3CompletedSanofiDec 200620,506
NCT00077753Venous Thromboembolism · United States, Argentina, Australia and more4CompletedSanofiOct 20064,726
NCT00043784Angina, Unstable · United States3CompletedSanofiFeb 20058,000

How it is read

Names in the registry

  • “Enoxaparin”, 11 entries
  • “Enoxaparin sodium”, 5 entries
  • “Enoxaparine”, 3 entries
  • “enoxaparin”, 3 entries
  • “Enoxaparin Sodium”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.